This report covers the 7MM (US, 5EU, Japan) and provides an Excel-based forecast model for the obesity market through 2035.
– In 2025, GlobalData estimated the total obesity market to be valued at $34.6 billion across the 7MM, with the US accounting for 82.6% of the market. Over the forecast period, the obesity market is anticipated to grow to a value of $118.2 billion in 2035.
– There will be an increase in therapies with longer duration of action, such as Novo’s CagriSema (semaglutide + cagrilintide) and zenagamtide, Eli Lilly’s tirzepatide and retatrutide, and Amgen’s MariTide, consequently improving patient compliance for obesity patients who may already experience a heavy treatment burden due to comorbid conditions.
– Multi-organ label expansion is broadening the clinical and reimbursement rationale, with glucagon-like peptide 1 (GLP-1) agents moving beyond weight loss and type 2 diabetes (T2D) and into cardiovascular risk reduction, metabolic dysfunction-associated steatohepatitis (MASH), and chronic kidney disease (CKD), among other indications.
– Therapies with new routes of administration will enter the market, such as Novo’s Wegovy pill (oral semaglutide), Eli Lilly’s Foundayo (orforglipron), Structure Therapeutics’ GSBR-1290, and other oral agents with different mechanisms of actions, such as enobosarm.
Scope of Report
Overview of obesity, including epidemiology, symptoms, diagnosis, and disease management.
Annualized obesity therapeutics market revenue in 7MM (US, 5EU, and Japan), annual cost of therapy and treatment usage pattern in 2025 and forecast for 10 years to 2035.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the obesity therapeutics market.
Pipeline analysis, comprehensive data assessing emerging trends and mechanisms of action under development for obesity treatment. The most promising candidates in late-stage development are profiled.
Analysis of the current and future market competition in the 7MM obesity therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
Reasons to buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the obesity therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the obesity therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Key Stakeholders
Table of Contents
Tables
Table 1: Obesity: Key metrics in the 7MM
Table 2: Classifications of obesity as outlined by the WHO
Table 3: Classification systems for obesity based on BMI cutoff points
Table 4: Risk factors and comorbidities for overweight and obesity
Table 5: Treatment guidelines for obesity
Table 6: Top 10 deals by value, 2021-26
Table 7: Obesity market – drivers and barriers in the 7MM, 2025–35
Table 8: Key events impacting sales for obesity in the US, 2025–35
Table 9: Obesity market – drivers and barriers in the US, 2025–35
Table 10: Key events impacting sales for obesity in the 5EU, 2025–35
Table 11: Obesity market – drivers and barriers in the 5EU, 2025–35
Table 12: Key events impacting sales for obesity in Japan, 2025–35
Table 13: Obesity market – drivers and barriers in Japan, 2025–35
Table 14: High-prescribing physicians surveyed, by country
Graphs
Figure 1: Global sales forecast by country for obesity in 2025 and 2035
Figure 2: Analysis of the company portfolio gap in obesity during the forecast period
Figure 3: Competitive assessment of the late-stage pipeline agents that GlobalData expects to be licensed for the treatment of obesity during the forecast period
Figure 4: Competitive assessment of the late-stage pipeline agents that GlobalData expects to be licensed for the treatment of obesity during the forecast period
Figure 5: Factors involved in the etiology of obesity
Figure 6: Pathophysiological manifestation of obesity
Figure 7: 7MM, total prevalence of overweight, men and women, %, ≥5 years, 2015–35
Figure 8: 7MM, total prevalence of obesity, men and women, %, ≥5 years, 2015–35
Figure 9: 7MM, sources used to forecast the total and diagnosed prevalent cases of overweight
Figure 10: 7MM, sources used to forecast the total and diagnosed prevalent cases of obesity
Figure 11: 7MM, sources used to forecast the total and diagnosed prevalent cases of overweight by BMI class
Figure 12: 7MM, sources used to forecast the total and diagnosed prevalent cases of obesity by BMI class
Figure 13: 7MM, sources used to forecast the total and diagnosed prevalent cases of pediatric obesity by severity
Figure 14: 7MM, sources used to forecast the diagnosed prevalent cases of obesity by comorbidity
Figure 15: 7MM, total prevalent cases of overweight, N, both sexes, age ≥5 years, 2025
Figure 16: 7MM, total prevalent cases of obesity, N, both sexes, age ≥5 years, 2025
Figure 17: 7MM, diagnosed prevalent cases of overweight, N, both sexes, age ≥5 years, 2025
Figure 18: 7MM, diagnosed prevalent cases of overweight by age, N, both sexes, age ≥5 years, 2025
Figure 19: 7MM, diagnosed prevalent cases of overweight by sex, N, both sexes, age ≥5 years, 2025
Figure 20: 7MM, diagnosed prevalent cases of overweight by BMI class, N, both sexes, age ≥5 years, 2025
Figure 21: 7MM, diagnosed prevalent cases of obesity, N, both sexes, age ≥5 years, 2025
Figure 22: 7MM, diagnosed prevalent cases of obesity by age, N, both sexes, age ≥5 years, 2025
Figure 23: 7MM, diagnosed prevalent cases of obesity by sex, N, both sexes, age ≥5 years, 2025
Figure 24: 7MM, diagnosed prevalent cases of pediatric obesity by severity, N, both sexes, ages 5─17, 2025
Figure 25: 7MM, diagnosed prevalent cases of obesity by BMI class, N, both sexes, age ≥18 years, 2025
Figure 26: 7MM, diagnosed prevalent cases of obesity by comorbidity, N, both sexes, age ≥18 years, 2025
Figure 27: BMI chart as a diagnostic technique for obesity
Figure 28: Treatment algorithm for obesity
Figure 29: Unmet needs and opportunities in obesity
Figure 30: Overview of the development pipeline in obesity
Figure 31: Key late-stage trials for the promising pipeline agents that GlobalData expects to be licensed for the treatment of obesity in the 7MM during the forecast period
Figure 32: Competitive assessment of the recently approved agents and late-stage pipeline agents that GlobalData expects to be licensed for the treatment of obesity during the forecast period
Figure 33: Competitive assessment of the pipeline drugs benchmarked against standard of care
Figure 34: Analysis of the company portfolio gap in obesity during the forecast period
Figure 35: 7MM sales forecast by country for obesity in 2025 and 2035
Figure 36: 7MM sales forecast by drug for obesity in 2025 and 2035
Figure 37: Sales forecast by drug class for obesity in the US in 2025 and 2035
Figure 38: Sales forecast by drug for obesity in the 5EU in 2025 and 2035
Figure 39: Sales forecast by drug for obesity in Japan in 2025 and 2035







